Small immunomodulatory molecules are an emerging class of cancer therapies. Due to quick clearance by the body (1-2 hrs), 3 - 4 injections/month are required. This increases the risk of infection, the cancer spreading, and lowers patient adherence. Our novel drug delivery platform technology provides delayed release (3-100 days) to simplify the treatment to just one monthly injection. We will start with skin, breast and pancreatic cancer patients, resulting in an initial market of $27+B.
Connect with Asan Therapeutics
